Abbott has announced the FDA approved the Masters HP 15mm rotatable mechanical heart valve, the world's smallest mechanical heart valve,...
RedHill Biopharma has announced that the positive final results, announced in June 2015, of the first Phase III study with...
RedHill Biopharma has announced successful final results from the first Phase III clinical study with RHB 105 for the eradication...
Ascendis Pharma A/S announced that top-line data from the randomized, double-blind, placebo-controlled portion of its Phase III PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP) which demonstrated statistically significant improvement with TransCon PTH compared to control on the primary composite endpoint and all key secondary endpoints.
On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Agilus, intended for the treatment of malignant hyperthermia in combination with adequate support measures.The applicant for this medicinal product is Norgine B.V.